Bleeding and thrombotic complications of kidney disease

Blood Reviews

Volumn 25, Issue 6, 2011, Pages 271-278

  Pavord, Sue ^a   Myers, Bethan ^b,c  

^a UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

^b UNITED LINCOLNSHIRE HOSPITALS NHS TRUST   (United Kingdom)

^c NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Bleeding; Kidney disease; Renal failure; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; ARGATROBAN; CALCINEURIN INHIBITOR; CITRIC ACID; CLOPIDOGREL; CONJUGATED ESTROGEN; DALTEPARIN; DANAPAROID; DESMOPRESSIN; ENOXAPARIN; HEPARIN; HEPARINOID; HIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; NAFAMSTAT; PROSTACYCLIN; PROTAMINE; RECOMBINANT ERYTHROPOIETIN; TICLOPIDINE; TINZAPARIN; TRANEXAMIC ACID; WARFARIN;

ARTERY THROMBOSIS; ARTICLE; BLEEDING; CONTINUOUS HEMOFILTRATION; CONTINUOUS INFUSION; CRYOPRECIPITATE; DEEP VEIN THROMBOSIS; DISEASE SEVERITY; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG WITHDRAWAL; ERYTHROCYTE TRANSFUSION; HEADACHE; HEART MUSCLE ISCHEMIA; HEMODIALYSIS; HEPARIN INDUCED THROMBOCYTOPENIA; HOT FLUSH; HUMAN; HYPOTENSION; KIDNEY DISEASE; KIDNEY DYSFUNCTION; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; PREVALENCE; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; SINGLE DRUG DOSE; THROMBOCYTE TRANSFUSION; THROMBOSIS; THROMBOSIS PREVENTION; UREMIA; VEIN THROMBOSIS;

ANIMALS; HEMORRHAGE; HUMANS; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; RENAL DIALYSIS; THROMBOSIS;

EID: 80055017091     PISSN: 0268960X     EISSN: 15321681     Source Type: Journal    
DOI: 10.1016/j.blre.2011.07.001     Document Type: Article

References (123)

1. Roderick P., Davies R., Jones C., Feest T., Smith S., Farrington K. Stimulation model of renal replacement therapy: predicting future demand in England. Nephrol Dial Transplant 2004, 19:692-701.
2. Levey A.S., Eckardt K.-U., Tsukamoto Y., et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005, 67:2089-2100.
3. Fiaccadori E., Maggiore U., Clima B., Melfa L., Rotelli C., Borgetti A. Incidence, risk factors and prognosis of gastrointestinal haemorrhage complicating acute renal failure. Kidney Int 2001, 59:1510-1519.
4. Castaldi P.A., Rozenberg M.C., Stewart J.H. The bleeding disorder of uraemia. A qualitative platelet defect. Lancet 1966, 2:66-69.
5. Carvalho A.C. Bleeding in a uremia - a clinical challenge. N Engl J Med 1983, 308:38-39.
6. Mellion B.T., Ignarro L.J., Ohlstein E.H., Pontecorvo E.G., Hyman A.L., Kadowitz P.J. Evidence for the inhibitory role of guanosine 3',5'-monophosphate in ADP-induced human platelet aggregation in the presence of nitric oxide and related vasodilators. Blood 1981, 57:946-955.
7. Tatesona J.E., Moncadaa S., Vanea J.R. Effects of prostacyclin (PGX) on cyclic AMP concentrations in human platelets. Prostaglandins 1977, 13:389-397.
8. Zupan I.P., Sabovic M., Salobir B., Ponikvar J.B., Cemelc P. Utility of in-vitro closure time test for evaluating platelet-related primary hemostasis in dialysis patients. Am J Kidney Dis 2003, 42:746-751.
9. Mannucci P.M., Remuzzi G., Ousineri F., et al. Deamino-8-D-arginine vasopressin shortens the bleeding time in uremia. N Engl J Med 1983, 308:8-12.
10. Kohler M., Hellstern P., Miyashita C., yon Blohm G., Wenzel E., et al. Subcutaneous injection of desmopressin (DDAVP): evaluation of a new, more concentrated preparation. Hemostasis 1989, 1:38-44.
11. Vigano G.L., Mannucci P., Lattuada A., Harris A., Remuzzi G. Subcutaneous desmopressin (DDAVP) shortens the bleeding time in uremia. Am J Hematol 1989, 31:32-35.
12. Janson P.A., Jubelirer S.J., Weinstein M.J., Deykin D. Treatment of the bleeding tendency in uremia with cryoprecipitate. N Engl J Med 1980, 303:1318-1322.
13. Triulzi N., Blumberg D.J. Variability in response to cryoprecipitate treatment for hemostatic defects in uremia. Yale J Biol Med 1990, 63:1-7.
14. Sabovic M., Lavre J., Vujkovac B. Tranexamic acid is beneficial as adjunctive therapy in treating major upper gastrointestinal bleeding in dialysis patients. Nephrol Dial Transplant 2003, 18:1388-1391.
15. Vigano G., et al. Recombinant human erythropoietin to correct uremic bleeding. Am J Kidney Dis 1991, 18:44-49.
16. Cases A., Escolar G., Riverter J.C., et al. Recombinant human erythropoietin treatment improves platelet function in uremic patients. Kidney Int 1992, 42:668-672.
17. Shemin D., Elnour M., Amarantes B., Abuelo J.G., Chazan J.A. Oral oestrogens decrease bleeding time and improve clinical bleeding in patients with renal failure. Am J Med 1990, 89:436-440.
18. Kim D., Kim H., Shin G., Ku S., Ma K., Shin S., et al. A randomized, prospective, comparitive study of manual and automated renal biopsies. Am J Kidney Dis 1998, 32:426-431.
19. Stevinkel P., Heimburger O., Paultre F., Diczfalusy U. Strong association between malnutrition, inflammation and atherosclerosis in chronic renal failure. Kidney Int 1999, 55:1899-1911.
20. Pecoits-Filho R., Lindholm B., Stenvinkel P. End-stage renal disease: a state of chronic inflammation and hyperleptinemia. Eur J Clin Invest 2003, 33:527-528.
21. Oberg B.P., McMenamin E., Lucas F.L., McMonagle E., Morrow J., Ikizler T.A., et al. Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int 2004, 65:1009-1016.
22. Landray M.J., Wheeler D.C., Lip G.Y.H., et al. Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney disease: the chronic renal impairment in Birmingham (CRIB) study. Am J Kidney Dis 2004, 43:244-253.
23. Sagripanti A., Cupistj A., Baicchi U., Ferdeghini M., Morelli E., Barsotfi G. Plasma parameters of the prothrombotic state in chronic uremia. Nephron 1993, 63:273-278.
24. Adams M.J., Irish A.B., Watts G.F., Oostryck R., Dogra G.K. Hypercoagulability in chronic kidney disease is associated with coagulation activation but not endothelial function. Thromb Res 2008, 123:374-380.
25. Vaziri N.D., Paule P., Toohey J. Acquired deficiency and urinary excretion of antithrombin III in nephrotic syndrome. Arch Intern Med 1984, 144:1802-1803.
26. Annuk M., Soveri I., Zilmer M., Lind L., Hulthe J., Fellström B. Endothelial function, CRP and oxidative stress in chronic kidney disease. J Nephrol 2005, 18:721-726.
27. Heinrich J., Sandkamp M., Kokott R., Schulte H., Assmann G. Relationship of lipoprotein(a) to variables of coagulation and fibrinolysis in a healthy population. Clin Chem 1991, 37:1950-1954.
28. Anglés-Cano E., Diaz A.de la Pena, Loyau S. Inhibition of fibrinolysis by lipoprotein(a). Ann N Y Acad Sci 2001, 936:261-275.
29. Goldwasser P., Avram M.M., Collier J.T., Michel M.A., Gusik S.A., Mittman N. Correlates of vascular access occlusion in hemodialysis. Am J Kidney Dis 1994, 24:785-794.
30. Fried L.F., Katz R., Cushman M., Sarnak M., Shlipak M.G., Kuller L., et al. Change in cardiovascular risk factors with progression of kidney disease. Am J Nephrol 2009, 29:334-341.
31. Foley R.N., Parfrey P.S., Sarnak M.J. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998, 32:S112-19.
32. N.B. Shulman, C.E. Ford, W.D. Hall. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function: results from the hypertension detection and follow-up program. The Hypertension Detection and Follow-Up Program Cooperative Group. Hypertension 1989;13(5 suppl):180-193.
33. P.M. Ridker, N. Rifai, L. Rose, J.E. Burning, N.R. Cook. Comparison of C-reactive protein and low density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347:15557-15565.
34. Monreal M., Falga C., Valle R. Venous thromboembolism in patients with renal insufficiency: findings from the RIETE Registry. Am J Med 2006, 119:1073-1079.
35. Falga C., Capdevila J.A., Soler S. Clinical outcome of patients with venous thromboembolism and renal insufficiency. Findings from the RIETE Registry. Thromb Haemost 2007, 98:771-776.
36. Wattanakit K., Cushman M., Stehman-Breen C., Heckbert S.R., Folsom A.R. Chronic kidney disease increases risk for venous thromboembolism. J Am Soc Nephrol 2008, 19:135-140.
37. Folsom A.R., Lutsey P.L., Astor B.C., Wattanakit K., Heckbert S.T., Cushman M. Chronic kidney disease and venous thromboembolism: a prospective study. Nephrol Dial Transplant 2010, 25:3296-3301.
38. Wattanakit K., Cushman M. Chronic kidney disease and venous thromboembolism: epidemiology and mechanisms. Curr Opin Pulm Med 2009, 15:408-412.
39. Attia J., Ray J., Cook D.J. Deep venous thrombosis and its prevention in critically ill adults. Arch Intern Med 2001, 161:1268-1279.
40. Cook D.J., Crowther M., Meade M. Deep venous thrombosis in medical-surgical ICU patients: prevalence, incidence and risk factors. Crit Care Med 2005, 33:1565-1571.
41. Hirsch D.R., Ingenito E.P., Goldhaber S.Z. Prevalence of deep venous thrombosis among patients in medical intensive care. JAMA 1995, 274:335-337.
42. Van Biesen W., De Bacquer D., Verbeke F., et al. The glomerular filtration rate in an apparently healthy population and its relation with cardiovascular mortality during 10 years. Eur Heart J 2007, 28:478-483.
43. Ocak G., Verduijn M., Vossen C.Y., et al. Chronic kidney disease stages 1-3 increase the risk of venous thrombosis. J Thromb Haemost 2010, 8:2428-2435.
44. Joffe H.V., Kucher N., Tapson V.F. Upper-extremity deep vein thrombosis: a prospective registry of 592 patients. Circulation 2004, 110:1605-1611.
45. Bernardi E., Pesavento R., Prandoni P. Upper extremity deep venous thrombosis. Curr Opin Pulm Med 1999, 5:222-226.
46. Daneschvar H.L., Seddighzadeh A., Piazza G., Goldhaber S.Z. Deep vein thrombosis in patients with chronic kidney disease. Thromb Haemost 2008, 99:1035-1039.
47. Mahmoodi B.K., ten Kate M.K., Waanders F., Veeger N.J., Brouwer J.L., Vogt L., et al. High absolute risks and predictors of venous and arterial thromboembolic events in patients with nephrotic syndrome: results from a large retrospective cohort study. Circulation 2008, 117:224-230.
48. Hull R., Goldsmith D. Nephrotic syndrome in adults. BMJ 2008, 336:1185.
49. Vaziri N.D., Paule P., Toohey J., Hung E., Alikhani S., Darwish R., et al. Acquired deficiency and urinary excretion of antithrombin III in nephrotic syndrome. Arch Intern Med 1984, 144:1802-1803.
50. Xu H., Chen K., Lin D., Dai L., Chen H., Xu Z. Cerebral venous sinus thrombosis in adult nephrotic syndrome. Clin Nephrol 2010, 74:144-149.
51. Wang Y.C., Chuang F.R., Lee W.C., Chen T.C., Ko S.F., Wang I.K., et al. Low-molecular-weight heparin successfully used to treat a nephrotic patient complicated by superior mesenteric vein thrombosis and portal vein thrombosis. Med Princ Pract 2011, 20:196-199.
52. Cameron J.S. Coagulation and thromboembolic complications in the nephrotic syndrome. Adv Nephrol 1984, 13:75-113.
53. Singhal R., Brimble K.S. Thromboembolic complications in the nephrotic syndrome: pathophysiology and clinical management. Thromb Res 2006, 118:397-407.
54. Bellomo R., Atkins R.C. Membranous nephropathy and thromboembolism: is prophylactic anticoagulation warranted?. Nephron 1993, 63:249-254.
55. Llach F., Papper S., Massry S.G. The clinical spectrum of renal vein thrombosis: acute and chronic. Am J Med 1980, 69:819-827.
56. Kayali F., Najjar R., Aswad F., Matta F., Stein P.D. Venous thromboembolism in patients hospitalizedwith nephrotic syndrome. Am J Med 2008, 121:226-230.
57. Mahmoodi B.K., ten Kate M.K., Waanders F., Veeger N.J., Brouwer J.L., Vogt L., et al. High absolute risks and predictors of venous and arterial thromboembolic events in patients with nephrotic syndrome: results from a large retrospective cohort study. Circulation 2008, 117:224-230.
58. Cameron J.S., Ogg C.S., Wass V. The complications of the nephrotic syndrome. The nephrotic syndrome 1985, New York Decker. J.S. Cameron, R.J. Glassrock (Eds.).
59. Geerts W.H., Jay R.M., Code K.I., et al. A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma. N Engl J Med 1996, 335:701-707.
60. Geerts W.H., Pineo G.F., Heit J.A. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004, 126(3 Suppl):338-400.
61. Wein L., Wein S., Haas S.J., Shaw J., Krum H. Pharmacological venous thromboembolism prophylaxis in hospitalized medical patients: a meta-analysis of randomized controlled trials. Arch Intern Med 2007, 167:1476-1486.
62. Weitz J.I. Low-molecular-weight heparins. N Engl J Med 1997, 337:688-699.
63. Lim W., Dentali F., Eikelboom J.W., Crowther M.A. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med 2006, 144:673-684.
64. Chow S., Zammit K., West K. Correlation of antifactor Xa concentrations with renal function in patients on enoxaparin. J Clin Pharmacol 2003, 43:586-590.
65. Geerts W.H., Bergqvist D., Pineo G.F., Heit J.A., Samama C.M., Lassen M.R., et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008, 133:381s-453s.
66. Hirsh J., Bauer K.A., Donati M.B., Gould M., Samama M.M., Weitz J.I., et al. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008, 133:141S-159S.
67. Ravaud P., Durieux P., Fourcade A. Prophylaxis of postoperative venous thrombosis: recommendations from l'assistance publique des hospitaux de Paris. Sangue Thromb Vaisseaux 1995, 7:119-129. Comite Scientifique Thrombose AP-HP.
68. Rabbat C., Cook D.J., Crowther M.A. Dalteparin thromboprophylaxis for critically ill medical-surgical patients. J Crit Care 2005, 20:357-363.
69. Sanderink G.J., Guimart C.G., Ozoux M.L., Jariwala N.U., Shukla U.A., Boutouyrie B.X. Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4days in patients with renal impairment. Thromb Res 2002, 105:225-231.
70. Samama M.M., Gerotziafas G.T. Comparative pharmacokinetics of LMWHs. Semin Thromb Hemost 2000, 26:31-38.
71. Mahé I., Aghassarian M., Drouet L., Bal Dit-Sollier C., Lacut K., Heilmann J.J., et al. Tinzaparin and enoxaparin given at prophylactic dose for eight days in medical elderly patients with impaired renal function: a comparative pharmacokinetic study. Thromb Haemost 2007, 97:581-586.
72. Siguret V., Pautas E., Février M., Wipff C., Durand-Gasselin B., Laurent M., et al. Elderly patients treated with tinzaparin (Innohep) administered once daily (175 anti-Xa IU/kg): anti-Xa and anti-IIa activities over 10days. Thromb Haemost 2000, 84:800-804.
73. Pautas E., Gouin I., Bellot O., Andreux J.P., Siguret V. Safety profile of tinzaparin administered once daily at a standard curative dose in two hundred very elderly patients. Drug Saf 2002, 25:725-733.
74. Tincani E., Mannucci C., Casolari B. Safety of dalteparin for the prophylaxis of venous thromboembolism in elderly medical patients with renal insufficiency: a pilot study. Haematologica 2006, 97:976-979.
75. Rabbat C., Cook D.J., Crowther M.A. Dalteparin thromboprophylaxis for critically ill medical-surgical patients. J Crit Care 2005, 20:357-363.
76. Douketis J., Cook D., Meade M., Guyatt G., Geerts W., Skrobik Y., et al. Canadian Critical Care Trials. Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study. Arch Intern Med 2008, 168:1805-1812.
77. Lim W., Cook D.J., Crowther M.A. Safety and efficacy of low molecular weight heparins for hemodialysis in patients with end-stage renal failure: a meta-analysis of randomized trials. J Am Soc Nephrol 2004, 15:3192-3206.
78. Nagge J., Crowther M., Hirsh J. Is impaired renal function a contraindication to the use of low-molecular-weight heparin?. Arch Intern Med 2002, 162:2605-2609.
79. Schmid P., Fischer A.G., Wuillemin W.A. Low-molecular-weight heparin in patients with renal insufficiency. Swiss Med Wkly 2009, 139:438-452.
80. Cardigan R.A., Mcgloin H., Mackie I.J., Machin S.J., Singer M. Activation of the tissue factor pathway occurs during continuous venovenous hemofiltration. Kidney Int 1999, 55:1568-1574.
81. Pawlak K., Pawlak D., Mysliwiec M. Association between tissue factor, its pathway inhibitor and oxidative stress in peritoneal dialysis patients. Blood Coagul Fibrinolysis 2007, 18:467-471.
82. Costa E., Rocha S., Rocha-Pereira P., Castro E., Reis F., Teixeira F., et al. Cross-talk between inflammation, coagulation/fibrinolysis and vascular access in hemodialysis patients. J Vasc Access 2008, 9:248-253.
83. Saltissi D., Morgan C., Westhuyzen J., Healy H. Comparison of low-molecular-weight heparin (enoxaparin sodium) and standard unfractionated heparin for haemodialysis anticoagulation. Nephrol Dial Transplant 1999, 14:2698-2703.
84. Sabry A., Taha M., Al Fawzan F., Alsaran K. Anticoagulation therapy during haemodialysis: a comparative study between two heparin regimens. Blood Coagul Fibrinolysis 2009, 20:57-62.
85. Fischer K.G. Essentials of anticoagulation in hemodialysis. Hemodial Int 2007, 11:178-189.
86. Sagedal S., Hartmann A., Sundstrom K. Anticoagulation intensity sufficient for haemodialysis does not prevent activation of coagulation and platelets. Nephrol Dial Transplant 2001, 16:987-993.
87. Schmitt Y., Schneider H. Low-molecular-weight herapin (LMWH): influence on blood lipids in patients on chronic haemodialysis. Nephrol Dial Transplant 1993, 8:438-442.
88. Arnadottir M., Kurkus J., Nilsson-Ehle P. Different types of heparin in hemodialysis: long term effects on postheparin lipases. Scand J Clin Lab Invest 1994, 54:515-521.
89. Kronenberg F., König P., Lhotta K., Steinmetz A., Dieplinger H. Low molecular weight heparin does not necessarily reduce lipids and lipoproteins in hemodialysis patients. Clin Nephrol 1995, 43:399-404.
90. McMahan D.A., Smith D.M., Carey M.A., Zhou X.H. Risk of major hemorrhage for outpatients treated with warfarin. J Gen Intern Med 1998, 13:311-316.
91. Biggers J.A., Remmers A.R., Glassford D.M., Sarles H.E., Lindley J.D., Fish J.C. The risk of anticoagulation in hemodialysis patients. Nephron 1977, 18:109-113.
92. Bennett W.M. Should dialysis patients ever receive warfarin and for what reasons?. Clin J Am Soc Nephrol 2006, 1:1357-1359.
93. Price P.A., Faus S.A., Williamson M.K. Warfarin causes rapid calcification of the elastic lamellae in rat arteries and heart valves. Arterioscler Thromb Vasc Biol 1998, 18:1400-1407.
94. Reynolds J.L., Joannides A.J., Skepper J.N., McNair R., et al. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol 2004, 15:2857-2867.
95. Danziger J. Vitamin K-dependent proteins, warfarin, and vascular calcification. Clin J Am Soc Nephrol 2008, 3:1504-1510.
96. Kim S.B., Lee S.K., Park J.S., Chi H.S., Hong C.D., Yang W.S. Effects of fixed low-dose warfarin on hemostatic factors in continuous ambulatory peritoneal dialysis patients. Am J Kidney Dis 2001, 37:343-347.
97. Traynor J.P., Walbaum D., Woo Y.M., Teenan P., Fox J.G., Mactier R.A. Low-dose warfarin fails to prolong survival of dual lumen venous dialysis catheters. Nephrol Dial Transplant 2001, 16:645.
98. Mokrzycki M.H., Kernilde J.-J., Rush H., Zdunek M.P., Rosenberg S.O. A randomized trial of minidose warfarin for the prevention of late malfunction in tunneled, cuffed hemodialysis catheters. Kidney Int 2001, 59:1935-1942.
99. Crowther* Mark A., Clase* Catherine M., Margetts* Peter J., Julian† Jim, Lambert* Kim, Sneath‡ Denise, et al. Low-intensity warfarin is ineffective for the prevention of PTFE graft failure in patients on hemodialysis: a randomized controlled trial. J Am Soc Nephrol 2002, 13:2331-2337.
100. Livio M., Benigni A., Vigano G., Mecca G., Remuzzi G. Moderate doses of aspirin and risk of bleeding in renal failure. Lancet 1986, 1:414-416.
101. Kaufman J.S., O'Connor T.Z., Zhang J.H., Cronin R.E., Fiore L.D., Ganz M.B., et al. Thrombosis, Veterans Affairs Cooperative Study Group on hemodialysis access graft. Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis. J Am Soc Neprhol 2003, 14:2313-2321.
102. Freeman R.V., Mehta R.H., Al Badr W., Cooper J.V., Kline-Rogers E., Eagle K.A. Influence of concurrent renal dysfunction on outcomes of patients with acute coronary syndromes and implications of the use of glycoprotein IIb/IIIa inhibitors. Am Coll Cardiol 2003, 41:718-724.
103. Ethier J., Bragg-Gresham J.L., Piera L., Akizawa T., et al. Aspirin prescription and outcomes in hemodialysis patients: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2007, 50:602-611.
104. Dember L.M., et al. Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis:a randomized controlled trial. JAMA 2008, 299:2164-2171.
105. Gröntoft K.C., Larsson R., Mulec H., Weiss L.G., Dickinson J.P. Fistula Study Group. Effects of ticlopidine in AV-fistula surgery in uremia. Scand J Urol Nephrol 1998, 32:276-283.
106. Salmon J., Cardigan R., Mackie I., Machin S., Singer M. Continuous venovenous haemofiltration using polyacrylonitrile filters does not activate contact system and intrinsic coagulation pathways. Intensive Care Med 1997, 23:38-43.
107. Bouman C.S., de Pont A.C., Meijers J.C., Bakhtiari K., Roem D., Zeerleder S., et al. The effects of continuous venovenous hemofiltration on coagulation activation. Crit Care 2006, 10:R150.
108. Tolwani A.J., Wille K.M. Anticoagulation for continuous renal replacement therapy. Semin Dial 2009, 22:141-145.
109. Schetz M., Wille K.M. Anticoagulation in continuous renal replacement therapy. Contrib Nephrol 2001, 132:283-303.
110. Joannidis M., Kountchev J., Rauchenzauner M., Schusterschitz N., Ulmer H., Mayr A., et al. Enoxaparin vs. unfractionated heparin for anticoagulation during continuous veno-venous hemofiltration: a randomized controlled crossover study. Intensive Care Medicine 2007, 33:1571-1579.
111. Yamamoto S., Koide M., Matsuo M., Suzuki S., Ohtaka M., Saika S., et al. Heparin-induced thrombocytopenia in hemodialysis patients. Am J Kidney Dis 1996, 28:82-85.
112. Finazzi G., Remuzzi G. Heparin-induced thrombocytopenia-background and implications for haemodialysis. Nephrol Dial Transplant 1996, 11:2120-2122.
113. Gupta A.K., Kovacs M.J., Sauder D.N. Heparin-induced thrombocytopenia. Ann Pharmacother 1998, 32:55-59.
114. Torry R.J., Labarrere C.A., Gargiulo P., Faulk W.P. Natural anticoagulant and fibrinolytic pathways in renal allograft failure. Transplantation 1994, 58:926-931.
115. Wang Y., Turner N., An S.F., Fleming K.A., Thompson E.M. Gene expression of plasminogen activator inhibitor 1 in transplant kidneys complicated by renal vein thrombosis: a combined study by in-situ hybridization and immunohistochemistry. Nephrol Dial Transplant 1994, 9:296-303.
116. Deira J., Alberca I., Lerma J.L., Martín B., Tabernero J.M. Changes in coagulation and fibrinolysis in the postoperative period immediately after kidney transplantation in patients receiving OKT3 or cyclosporine A as induction therapy. Am J Kidney Dis 1998, 32:575-581.
117. Patrassi G.M., Sartori M.T., Rigotti P., Di Landro D., Theodoridis P., Fioretti M., et al. Reduced fibrinolytic potential one year after kidney transplantation: relationship to long-term steroid treatment. Transpantation 1995, 59:1416-1420.
118. Irish A.B., Green F.R. Environmental and genetic determinants of the hypercoagulable state and cardiovascular disease in renal transplant recipients. Nephrol Dial Transplant 1997, 12:167-173.
119. Ojo Akinlolu O., Hanson Julie A., Wolfe Robert A., Agodoa Lawrence Y., Leavey Sean F., Leichtman Alan Dialysis modality and the risk of allograft thrombosis in adult renal transplant recipients. Kidney Int 1999, 55:1952-1960.
120. Bakir N., Sluiter W.J., Ploeg R.J., van Son W.J., Tegzess A.M. Primary renal graft thrombosis. Nephrol Dial Transplant 1996, 11:140-147.
121. Ducloux D., Motte G., Challier B., Gobey R., Chalopin J.-M. Serum total homocysteine and cardiovascular disease occurrence in chronic, stable renal transplant recipients: a prospective study. J Am Soc Nephrol 2000, 11:134-137.
122. Bostom A.G., Gohh R.Y., Beaulieu A.J., Nadeau M.R., et al. Treatment of hyperhomocysteinemia in renal transplant recipients:a randomized, placebo-controlled trial. Annals Int Med 1997, 127:1089-1092.
123. Schnyder G., Roffi M., Pin R., Flammer Y., et al. Decreased rate of coronary restenosis after lowering of plasma homocystine levels. N Engl J Med 2001, 345:1593.